Lipid metabolism in health and disease: Mechanistic and therapeutic insights for Parkinson's disease.
10.1097/CM9.0000000000003627
- Author:
Bingqing QIN
1
;
Yuan FU
2
;
Ana-Caroline RAULIN
3
;
Shuangyu KONG
1
;
Han LI
1
;
Junyi LIU
4
;
Chunfeng LIU
1
;
Jing ZHAO
1
Author Information
1. Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China.
2. Department of Neurology, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310009, China.
3. Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
4. Department of Neurology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, Jiangsu 215000, China.
- Publication Type:Review
- Keywords:
Cholesterol;
Fatty acids;
Glycerophospholipids;
Lipid metabolism;
Lipoproteins;
Parkinson’s disease;
Sphingolipids
- MeSH:
Humans;
Parkinson Disease/metabolism*;
Lipid Metabolism/physiology*;
Animals;
Oxidative Stress/physiology*;
alpha-Synuclein/metabolism*
- From:
Chinese Medical Journal
2025;138(12):1411-1423
- CountryChina
- Language:English
-
Abstract:
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons and the accumulation of Lewy bodies, leading to motor and nonmotor symptoms. While both genetic and environmental factors contribute to PD, recent studies highlight the crucial role of lipid metabolism disturbances in disease progression. Altered lipid homeostasis promotes protein aggregation and oxidative stress, with significant changes in lipid classes such as sphingolipids and glycerolipids observed in patients with PD. These disturbances are involved in key pathological processes, such as α-synuclein aggregation, organelle dysfunction, lipid-mediated neuroinflammation, and impaired lipid homeostasis. This review examines the relationship between lipid species and PD progression, focusing on the physiological roles of lipids in the central nervous system. It explores the mechanistic links between lipid metabolism and PD pathology, along with lipid-related genetic risk factors. Furthermore, this review discusses lipid-targeting therapeutic strategies to mitigate PD progression, emphasizing the potential of lipid modulation for effective treatment development.
